
By ZetaKap : Interested in biotechnology companies? Do you prefer companies with high liquidity? Do you prefer investing in stocks that analysts have weighed in on? We ran a screen you might find helpful. The Current ratio is a liquidity ratio used to determine a company's financial health. The ...
By Ganaxi Small Cap Movers : New York-based Orbimed Advisors is the world's largest healthcare investment firm, with over $5 billion in assets under management, including $3.37 billion in 13-F assets per its most recent Q1 2012 filing , up from $3.05 billion in the prior quarter Complete Story »
optimism. They were toughly optimistic. They were in-your-face optimistic. But I do like it." Vertex ( VRTX ), Celgene ( CELG ): "I think (Vertex) goes remarkably higher. It has done lots of back and forth. It could go to $80. I think it is the
By Markus Aarnio : Since my last article in February about Myrexis ( MYRX ) we have seen a small pop in the share price and a subsequent drop as well. The pop was due to a press release given on February 15th stating that company's Board of Directors has retained Stifel Nicolaus Weisel, an ...
By Kapitall : Do you follow company sales trends? Most companies rely on sales as their primary source of profits, so a sales analysis should be high on the list. To illustrate, we ran a screen. We began by screening the biotech industry for stocks with high growth prospects, with 5-year projected
By Dividendinvestr : By Renee O'Farrell Healthcare costs have been on the rise. Annual medical costs increased almost 35% from 2006 to 2010, with healthcare spending rising 8% a year (read more about it here ). While this fact might hit consumers hard, for investors, it is great news. Between ...
appetite "for immediate, stable income amid today's low interest rate environment." Names Moody's throws out are Lab Corp. ( LH ), Life Tech ( LIFE ), Celgene ( CELG ), Biogen ( BIIB ) and CareFusion ( CFN ). Post your comment!
composition of matter and method of use patents on Abraxane begin to expire in 2013, opening the door for generic challenges. Celgene CELG is amid a global expansion led by its blood cancer drug Revlimid, and the acquisitions of Pharmion, Gloucester, and Abraxis
By David Pinsen : In a recent blog post ("Can The Crowd Be More Patient?"), venture capitalist Fred Wilson explained the challenge of attracting early equity investment to drug discovery: One of the most noticeable changes to the VC business over the past decade is the movement of investment ...
Apple ( AAPL ), Starbucks ( SBUX ), Chipotle Mexican Grill ( CMG ), Ross Stores ( ROST ), Allergan ( AGN ), Celgene ( CELG ), Lululemon ( LULU ). Other stocks mentioned: Fossil ( FOSL ), Bed Bath and Beyond ( BBBY ), Macy's ( M ) Cramer discussed